Because of the risk of developing severe neutropenia, the Food and Drug Administration (FDA) has required a special program called a Risk Evaluation and Mitigation Strategy (REMS) for clozapine.

The purpose of the Clozapine REMS Program is to make sure that the benefits of clozapine treatment outweigh the risks.

Prescribers must talk to their patients about the Clozpine REMS Program requirements and the risks of using clozapine. Patients should review the What You Need to Know About Clozapine and Neutropenia: A Guide for Patients and Caregivers program material and talk with their prescriber if they have any questions or concerns about using clozapine.

For additional information about the Clozapine REMS Program, please call 844-267-8678.